|
⚲
|
| Keyboard |
| EcoR1 Capital LLC | |
|---|---|
| Firm | |
| Address | 357 Tehama Street 3 San Francisco, CA 94103 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| EcoR1 Special Opportunity Fund III LP | 021-296123 | Executive Officer | |||
| EcoR1 Capital LLC | |||||
| EcoR1 Special Opportunity Fund II LP | 021-250824 | Executive Officer | 0.6 M | ||
| EcoR1 Special Opportunity Fund I LP | 021-234162 | Executive Officer | 8.8 M | ||
| EcoR1 Capital Fund LP | 021-191130 | Executive Officer | 117.8 M | 229.0 M | |
| EcoR1 Capital Fund Qualified LP | 021-211072 | Executive Officer | 1,811.4 M | 3,130.2 M | |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 2,077,779 | $18.00 | 37,400,022 |
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 128,506 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 202,862 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Conversion | 2,270,879 | ||
|
Aktis Oncology Inc AKTS
Common Stock
|
2026-01-12 | Buy | 144,443 | $18.00 | 2,599,974 |
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 9,913,810 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 997,299 | ||
|
Aktis Oncology Inc AKTS
Series A Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 488,891 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 2,397,500 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 965,190 | ||
|
Aktis Oncology Inc AKTS
Class A Common Stock · derivative
|
2026-01-12 | Conversion | 86,222 | ||
|
Aktis Oncology Inc AKTS
Series B Redeemable Convertible Preferred Stock · derivative
|
2026-01-12 | Conversion | 102,500 | ||
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-30 | Sell | 27,433,338 | $0.10 | 2,743,334 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-29 | Sell | 2,687,460 | $0.10 | 268,746 |
|
Adaptimmune Therapeutics PLC ADAP
Ordinary Shares
|
2025-07-28 | Sell | 33,931,740 | $0.11 | 3,732,491 |
|
Zymeworks Inc ZYME
Pre-Funded Warrants (right to acquire) · derivative
|
2025-06-26 | Option exercise | 5,086,521 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Option exercise | 5,086,480 | $0.00 | |
|
Zymeworks Inc ZYME
Common Stock
|
2025-06-26 | Tax withheld | 41 | $12.71 | 521 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-19 | Buy | 5,919 | $11.78 | 69,726 |
|
Zymeworks Inc ZYME
Common Stock
|
2025-05-15 | Buy | 49,502 | $11.43 | 565,808 |
| showing 20 of 159 most recent transactions | |||||